Stock listing

NASDAQ:AVLN Avalyn Pharma Inc. Stock

Home listing (NASDAQ) of Avalyn Pharma Inc.

Follow Avalyn Pharma Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:AVLN

$28.40 USD +0.71 (+2.6%)

Close on Nov 20, 2026

Past 6 months -3.7% · daily closes, Apr 30, 2026 – Nov 20, 2026, adjusted for splits
Day range
$27.85 – $29.38 USDNov 20, 2026
Volume
214,295 sharesNov 20, 2026
Market cap
$1.26B USDAt the close on Nov 20, 2026 · price × 44.33M shares outstanding
Traded on an average day
$10.04M USDMedian day 286,743 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Avalyn Pharma Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:AVLN · Home$28.40 USD+0.71 (+2.6%)214,295$28.06$29.38$27.85$27.69Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AVLN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$28.40+0.71+2.6%$28.06$29.38$27.85214,295
$27.69-0.23-0.8%$27.74$29.08$27.29404,890
$27.92-1.84-6.2%$29.76$29.76$27.04453,013
$29.76-0.52-1.7%$30.28$30.62$29.15329,069
$30.28-0.31-1.0%$30.57$30.84$29.30574,888
$30.59-1.03-3.3%$30.78$31.39$28.15499,880
$31.62+0.45+1.4%$31.07$31.87$30.67474,481
$31.17+1.67+5.7%$29.16$31.51$28.71478,189
$29.50+0.35+1.2%$29.75$30.74$28.56796,771
$29.15+2.48+9.3%$26.71$29.18$26.13630,263
$26.67-0.80-2.9%$27.58$27.97$26.26476,339
$27.47+0.66+2.5%$27.70$28.35$26.03455,275
$26.81+1.21+4.7%$25.87$26.96$25.45450,174
$25.60-0.03-0.1%$25.63$26.44$25.10445,062
$25.63-0.08-0.3%$25.71$26.17$24.85343,494
$25.71-0.03-0.1%$26.09$26.20$25.17593,264
$25.74-0.09-0.3%$25.68$26.74$24.821,085,546
$25.83-1.31-4.8%$27.00$27.19$25.28961,285
$27.14+1.10+4.2%$26.20$28.30$25.48411,020
$26.04-1.21-4.4%$27.21$27.21$25.43320,312
$27.25+2.14+8.5%$25.12$27.57$25.10286,743
$25.11+0.48+1.9%$24.74$25.57$22.99209,634
$24.63+1.30+5.6%$23.33$24.75$22.24217,518
$23.33-0.33-1.4%$23.95$24.30$23.07180,005
$23.66-0.98-4.0%$24.72$24.72$23.53291,400
$24.64+0.95+4.0%$23.88$25.14$23.59199,400
$23.69-0.05-0.2%$23.69$24.15$22.68267,800
$23.74-1.06-4.3%$24.66$25.27$23.08403,900
$24.80-0.96-3.7%$25.64$25.93$24.70133,300
$25.76+0.04+0.2%$25.70$26.33$25.22241,800
$25.72+0.19+0.7%$25.32$25.82$24.14883,800
$25.53+0.10+0.4%$25.30$26.31$25.26202,900
$25.43-1.60-5.9%$27.22$27.22$25.06260,600
$27.03-1.10-3.9%$27.98$28.21$26.26427,300
$28.13+0.71+2.6%$28.59$28.92$27.72526,200
$27.42-1.07-3.8%$28.48$28.69$26.86423,600
$28.49+1.39+5.1%$27.05$29.00$26.57347,600
$27.10-1.22-4.3%$27.67$28.67$27.01422,000
$28.32+0.24+0.9%$27.92$28.80$27.27205,900
$28.08-0.47-1.6%$28.52$28.53$27.00223,100
$28.55-1.12-3.8%$29.70$30.16$27.40221,200
$29.67-2.78-8.6%$32.19$32.54$29.14252,000
$32.45+0.83+2.6%$31.94$33.18$31.00233,300
$31.62+0.10+0.3%$31.34$33.00$30.97177,300
$31.52-1.91-5.7%$33.15$34.04$31.18664,800
$33.43-1.28-3.7%$35.26$35.46$31.77317,000
$34.71+0.43+1.3%$34.38$35.20$34.10244,500
$34.28-0.70-2.0%$35.01$35.53$32.59227,200
$34.98+1.41+4.2%$33.40$36.42$33.40494,100
$33.57-1.10-3.2%$35.15$35.39$33.56132,900
$34.67-1.21-3.4%$35.26$36.18$34.22129,100
$35.88-1.74-4.6%$37.30$37.69$35.60168,600
$37.62+0.23+0.6%$37.15$38.70$36.81302,175
$37.39+1.95+5.5%$35.21$38.34$34.90243,500
$35.44-0.14-0.4%$35.85$36.34$34.37150,900
$35.58+0.30+0.9%$35.29$36.21$34.62181,900
$35.28+0.55+1.6%$34.63$35.82$34.31183,600
$34.73+0.04+0.1%$34.52$35.61$34.22333,100
$34.69-1.82-5.0%$36.45$36.45$34.37202,900
$36.51-0.53-1.4%$36.82$37.52$36.19129,000
$37.04-1.16-3.0%$38.02$38.37$36.39142,600
$38.20+0.51+1.4%$37.99$39.11$37.87108,400
$37.69-0.68-1.8%$38.49$38.96$36.63158,400
$38.37+1.24+3.3%$37.13$39.68$37.06159,500
$37.13-1.84-4.7%$38.65$39.57$36.70179,300
Ticker
NASDAQ:AVLN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Avalyn Pharma Inc. news

Avalyn Pharma Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 16 in all · newest Nov 12, 2026 · oldest 2026
Decks
2 decks · latest September 2026

Where Avalyn Pharma Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:AVLN · Home listing · This pageNASDAQUnited StatesUSD
BOATS:AVLNBOATSUnited StatesUSD

Valuation

Price/book 3.4× against a median of 3.3×: 5th lowest of 9 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$946.4M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
3.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.12

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Avalyn Pharma Inc. · NASDAQ:AVLNUS$1.26BUS$946.4Mn/an/an/a3.4×n/a0.0×0.12
OliX Pharmaceuticals, Inc. · KRX:226950US$1.31BUS$1.17Bn/a114×n/a7.4×−102.9%0.1×n/a
Absci Corporation · NASDAQ:ABSIUS$1.30BUS$1.13Bn/a758×n/a5.9×n/a0.0×3.20
LB Pharmaceuticals Inc · NASDAQ:LBRXUS$1.26BUS$858.7Mn/an/an/a3.0×n/a0.0×0.81
MannKind Corporation · NASDAQ:MNKDUS$1.24BUS$1.46Bn/a3.5×309×n/a−18.1%n/a1.06
Novavax, Inc. · NASDAQ:NVAXUS$1.23BUS$902.3Mn/a2.2×n/an/a−18.6%n/a1.98
Silence Therapeutics PLC · NASDAQ:SLNUS$1.23BUS$984.6Mn/a2,159×n/a5.7×n/a0.0×1.07
Ocular Therapeutix, Inc. · NASDAQ:OCULUS$1.23BUS$774.9Mn/a15.4×n/a2.8×−648.6%0.2×1.35
Generate Biomedicines, Inc. · NASDAQ:GENBUS$1.22BUS$895.6Mn/a28.1×n/a3.2×−637.0%0.2×1.90
Taysha Gene Therapies, Inc. · NASDAQ:TSHAUS$1.21BUS$837.4Mn/a153×n/a3.4×n/a0.1×1.69
Mineralys Therapeutics, Inc. · NASDAQ:MLYSUS$1.21BUS$585.1Mn/an/an/a2.4×n/a0.0×1.39
Median of the othersUS$1.23BUS$899.0M71.3×309×3.3×−102.9%0.1×1.39

Forecasts

3 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
61.80 USD · Analysts' mean
EPS, year to Dec 2026
-2.69 · 1 analyst

Team and board

Officers

OfficerRole
Heather TurnerBoard Chair CEO, LB Pharma
Lyn BaranowskiChief Executive Officer
Doug CarlsonChief Financial Officer and Chief Business Officer
Melissa RhodesChief Operating Officer
Adam GoldenGeneral Counsel and Head of Business Development
Kelly DonoghueSr. Manager, IR and Corporate Communications
Craig ConoscentiSenior Vice President, Clinical Development
Frank SalisburySenior Vice President, Commercial
Jill DenningSenior Vice President, Clinical Development Operations
Jim BishopSenior Vice President, Business Operations
Kimberley CummingsSENIOR VICE PRESIDENT, REGULATORY AFFAIRS
Stephen PhamSenior Vice President, Product Development
David FriedmanMANAGING DIRECTOR AND SENIOR ANALYST, Suvretta Capital Management
Howard M. LazarusChief Medical Officer

Board

DirectorRole
Heather TurnerBoard Chair CEO, LB Pharma
Jill CarrollPartner, SR One
Lyn BaranowskiChief Executive Officer
Robert J. MeyerDirector

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open−3.3%
Q2 2026Aug 12, 2026 · Before open+5.4%
Q1 2026Jun 3, 2026 · Before open+2.6%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck37 slidesSeptember 2026
Technical Presentation (September 2023)Technical12 slidesSep 11, 2023

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$345M raised · US$18 a share · Morgan Stanley +3
Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Evercore ISI (co-lead), Guggenheim Securities (co-lead)
May 1, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$18.00 a share on Apr 29, 2026.

Price
US$18.00 a share
Shares offered
16,666,667 shares of common stock
Offering size
US$300 million
Underwriters' option
Up to 2,500,000 more shares
Listing
AVLN on the Nasdaq Global Select Market
Underwriters
Morgan Stanley, Jefferies, Evercore ISI, Guggenheim Securities · In the order on the cover
Shares delivered
On or about May 1, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceFeb 6, 2026
Filed publiclyApr 8, 2026
Amended twiceNewest Apr 29, 2026
Shares registered with an exchangeApr 27, 2026
Declared effective by the SECApr 29, 2026
Final prospectus, with the priceApr 30, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Apr 30, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024
Revenue00
Research and development76.6M45.8M
Selling, general and administrative14.7M11.4M
Operating income-91.3M-57.1M
Depreciation and amortization42.0K29.0K
EBITDA-91.3M-57.1M
Income before tax-85.2M-49.7M
Net income-85.2M-49.7M
Earnings per share, basic-2.04-1.19

Balance sheet

LineFY2025FY2024
Cash and equivalents52.3M24.0M
Short-term investments86.0M86.7M
Receivables537.0K591.0K
Current assets143.6M114.4M
Total assets148.9M124.5M
Accounts payable3.76M2.28M
Current liabilities14.1M8.74M
Total debt1.67M
Total liabilities387.5M299.0M
Shareholders' equity-238.7M-174.5M
Shares outstanding41.8M41.8M

Cash flow

LineFY2025FY2024
Cash from operations-81.5M-48.4M
Capital spending-344.0K-95.0K
Free cash flow-81.8M-48.5M
Cash from investing10.1M-91.5M
Cash from financing99.8M89.0K
Change in cash28.4M-139.8M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 19, 2026Insider tradeSEC
4 · Change in ownershipNov 19, 2026Insider tradeSEC
4 · Change in ownershipNov 19, 2026Insider tradeSEC
4 · Change in ownershipNov 19, 2026Insider tradeSEC
144 · Notice of proposed saleNov 17, 2026Other filingsSEC
144 · Notice of proposed saleNov 17, 2026Other filingsSEC
144 · Notice of proposed saleNov 17, 2026Other filingsSEC
144 · Notice of proposed saleNov 17, 2026Other filingsSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
All 74 filings
FilingDateTypeFiled with
8-K · Current reportNov 12, 2026ResultsSEC
4 · Change in ownershipSep 17, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 17, 2026Insider tradeSEC
8-K · Current reportSep 16, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 11, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 6, 2026Big-stake noticeSEC
8-K · Current reportJul 1, 2026Material contractSEC
8-K · Current reportJun 17, 2026Current reportSEC
10-Q · Quarterly reportJun 3, 2026Quarterly reportSEC
8-K · Current reportJun 3, 2026ResultsSEC
SCHEDULE 13D · Big-stake noticeMay 8, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeMay 8, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 7, 2026Big-stake noticeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 5, 2026Big-stake noticeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
8-K · Current reportMay 1, 2026Current reportSEC
S-8 · Registration statement for employee plansApr 30, 2026Offer documentSEC
424B4 · ProspectusApr 30, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 30, 2026Other filingsSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2026Insider tradeSEC
CERT · Exchange's certificate of listingApr 29, 2026Other filingsSEC
S-1/A · Registration statement, amendedApr 29, 2026Offer documentSEC
8-A12B · Registration of shares for listing on an exchangeApr 27, 2026Other filingsSEC
S-1/A · Registration statement, amendedApr 23, 2026Offer documentSEC
S-1 · Registration statementApr 8, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedMar 18, 2026Offer documentSEC
DRS · Draft registration statementFeb 6, 2026Offer documentSEC
DOct 10, 2023Other filingsSEC
DMay 7, 2020Other filingsSEC
D/AMay 24, 2017Other filingsSEC
DMar 24, 2017Other filingsSEC
D/AAug 12, 2015Other filingsSEC
D/AMar 24, 2015Other filingsSEC
DNov 16, 2012Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Avalyn Pharma Inc.’s releases · as of Aug 31, 2026

Common shares
44,333,095
Fully diluted
44,333,095

Fully diluted

LineSharesAs of
Common shares44,333,095Aug 31, 2026

Share count over time

CountShares
Aug 31, 202644,333,095

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Fidelity6.19MUS$176MSep 30, 2026
T. Rowe Price3.58MUS$102MSep 30, 2026
Novo Holdings A/S3.45MUS$98.3MSep 30, 2026
Sr One Capital Management, LP3.31MUS$94.3MSep 30, 2026
Perceptive Advisors LLC2.68MUS$76.2MSep 30, 2026
Montanova Capital, LLC2.5MUS$71.3MSep 30, 2026
Nvp Associates, LLC2.27MUS$64.6MSep 30, 2026
Wellington2.1MUS$60MSep 30, 2026
Catalio Capital Management, LP1.7MUS$48.4MSep 30, 2026
Eventide Asset Management, LLC1.38MUS$39.2MSep 30, 2026
All 109 holders
HolderSharesValueAs of
Bellevue Group AG1.35MUS$38.5MSep 30, 2026
BlackRock1.33MUS$37.7MSep 30, 2026
Vanguard1.02MUS$29.2MSep 30, 2026
Soleus Capital Management, L.P.1.02MUS$29MSep 30, 2026
Citadel959KUS$27.3MSep 30, 2026
Andera Partners930KUS$26.5MSep 30, 2026
Pivotal bioVenture Partners Investment Advisor LLC867KUS$24.7MSep 30, 2026
Jennison Associates LLC866KUS$24.7MSep 30, 2026
Tpg Gp A, LLC773KUS$22MSep 30, 2026
Braidwell LP744KUS$21.2MSep 30, 2026
Deerfield Management Company, L.P.731KUS$20.8MSep 30, 2026
Rock Springs Capital Management LP663KUS$18.9MSep 30, 2026
State Street554KUS$15.8MSep 30, 2026
Geode Capital471KUS$13.4MSep 30, 2026
ADAR1 Capital Management, LLC398KUS$11.3MSep 30, 2026
Silverarc Capital Management, LLC378KUS$10.8MSep 30, 2026
Baker Bros. Advisors LP350KUS$9.97MSep 30, 2026
Franklin Templeton332KUS$9.11MSep 30, 2026
Infinitum Asset Management, LLC275KUS$7.83MSep 30, 2026
Goldman Sachs192KUS$5.48MSep 30, 2026
UBS189KUS$5.39MSep 30, 2026
Federated Hermes, Inc.160KUS$4.56MSep 30, 2026
Schwab158KUS$4.5MSep 30, 2026
Woodline Partners LP151KUS$4.3MSep 30, 2026
Northern Trust143KUS$4.08MSep 30, 2026
Jones Hill Capital LP127KUS$3.61MSep 30, 2026
Stempoint Capital LP118KUS$3.36MSep 30, 2026
Atom Investors LP118KUS$3.35MSep 30, 2026
Burkehill Global Management, LP115KUS$3.28MSep 30, 2026
Acuta Capital Partners, LLC115KUS$3.27MSep 30, 2026
TD98,182US$2.66MSep 30, 2026
Blackstone Inc.97,985US$2.79MSep 30, 2026
Manufacturers Life Insurance Company, The95,558US$2.72MSep 30, 2026
Moore Capital Management, LP88,057US$2.51MSep 30, 2026
Adage Capital Partners Gp, L.L.C.80,000US$2.28MSep 30, 2026
Seven Grand Managers, LLC75,000US$2.14MSep 30, 2026
Ghisallo Capital Management LLC70,000US$1.99MSep 30, 2026
Bank of America57,862US$1.65MSep 30, 2026
Walleye Capital LLC54,581US$1.56MSep 30, 2026
Quadrature Capital Ltd47,469US$1.35MSep 30, 2026

Funds

HolderSharesValueAs of
Fidelity Small Cap Growth Fund1.23MUS$35.5MJul 31, 2026
Fidelity Small Cap Growth K6 Fund627KUS$18.1MJul 31, 2026
Vanguard Total Stock Market Index Fund534KUS$17.6MJun 30, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.416KUS$13.7MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.396KUS$13MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund386KUS$12.7MJun 30, 2026
T. Rowe Price Small-Cap Value Fund, Inc.342KUS$11.3MJun 30, 2026
iShares Russell 2000 ETF334KUS$11MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.332KUS$10.9MJun 30, 2026
PGIM Jennison Health Sciences Fund318KUS$9.17MMay 29, 2026
All 113 holders
HolderSharesValueAs of
Fidelity Blue Chip Growth Fund281KUS$8.1MJul 31, 2026
Fidelity Growth Company Fund268KUS$7.7MMay 31, 2026
T. Rowe Price Institutional Small-Cap Stock Fund218KUS$7.17MJun 30, 2026
Vanguard Extended Market Index Fund193KUS$6.34MJun 30, 2026
Fidelity Small Cap Index Fund187KUS$5.38MJul 31, 2026
Fidelity Advisor Biotechnology Fund162KUS$4.67MJul 31, 2026
Federated Hermes Kaufmann Small Cap Fund160KUS$4.61MJul 31, 2026
Franklin Biotechnology Discovery Fund120KUS$3.47MJul 31, 2026
Eventide Healthcare & Life Sciences Fund100KUS$3.29MJun 30, 2026
Vanguard Explorer Fund87,237US$2.51MJul 31, 2026
VIP Contrafund Portfolio86,900US$2.86MJun 30, 2026
iShares Russell 2000 Growth ETF85,401US$2.81MJun 30, 2026
Fidelity Advisor New Insights Fund77,100US$2.54MJun 30, 2026
Fidelity Growth Company K6 Fund74,257US$2.14MMay 31, 2026
Fidelity Small Cap Stock Fund73,400US$2.11MJul 31, 2026
Fidelity Series Growth Company Fund66,700US$1.92MMay 31, 2026
T. Rowe Price Small-Mid Cap ETF60,717US$2MJun 30, 2026
Fidelity Blue Chip Growth K6 Fund57,235US$1.65MJul 31, 2026
Fidelity Series Blue Chip Growth Fund52,200US$1.5MJul 31, 2026
Fidelity Series Opportunistic Insights Fund44,300US$1.46MJun 30, 2026
T.Rowe Price Small Cap Growth Portfolio43,485US$1.43MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity Fund41,758US$1.37MJun 30, 2026
Schwab Small-Cap Index Fund41,641US$1.2MJul 31, 2026
iShares Russell 2000 Value ETF37,771US$1.24MJun 30, 2026
Transamerica T. Rowe Price Small Cap VP28,042US$923KJun 30, 2026
Master Small Cap Index Series24,604US$810KJun 30, 2026
T. Rowe Price Health Sciences Portfolio24,376US$802KJun 30, 2026
Nuveen Small Cap Blend Index Fund22,752US$655KJul 31, 2026
The Hartford Healthcare Fund17,700US$510KJul 31, 2026
Strategic Advisers U.S. Total Stock Fund17,540US$505KMay 31, 2026
Schwab Total Stock Market Index Fund16,089US$463KJul 31, 2026
Vanguard Russell 2000 Index Fund15,835US$456KMay 31, 2026
Small Company Growth Portfolio15,611US$514KJun 30, 2026
Select Biotechnology Portfolio15,000US$432KMay 31, 2026
EQ/2000 Managed Volatility Portfolio14,146US$466KJun 30, 2026
T. Rowe Price Spectrum Moderate Growth Allocation Fund13,771US$396KMay 31, 2026
LVIP State Street Small-Cap Index Fund12,400US$408KJun 30, 2026
Brighthouse/Wellington Large Cap Research Portfolio11,584US$381KJun 30, 2026
Fidelity Small Cap Growth Index Fund11,053US$364KJun 30, 2026
Blackstone Alternative Multi-Strategy Fund9,863US$325KJun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Baranowski Lyn
Director, Officer: Chief Executive Officer
Sale6,465USD 27.90US$180KNov 18, 2026
Baranowski Lyn
Director, Officer: Chief Executive Officer
Sale735USD 28.36US$20,848Nov 18, 2026
Carlson Douglas R
Officer: See Remarks
Sale11,527USD 27.78US$320KNov 17, 2026
Carlson Douglas R
Officer: See Remarks
Sale3,093USD 28.22US$87,299Nov 17, 2026
Carlson Douglas R
Officer: See Remarks
Sale255USD 29.23US$7,453Nov 17, 2026
Rhodes Melissa
Officer: Chief Operating Officer
Sale10,875USD 27.79US$302KNov 17, 2026
Rhodes Melissa
Officer: Chief Operating Officer
Sale2,025USD 28.21US$57,119Nov 17, 2026
Rhodes Melissa
Officer: Chief Operating Officer
Sale400USD 29.23US$11,691Nov 17, 2026
Baranowski Lyn
Director, Officer: Chief Executive Officer
Sale39,600USD 27.76US$1.1MNov 17, 2026
Baranowski Lyn
Director, Officer: Chief Executive Officer
Sale5,300USD 28.15US$149KNov 17, 2026
All 22 trades
TradeTradeSharesPriceValueDate
Baranowski Lyn
Director, Officer: Chief Executive Officer
Sale400USD 29.22US$11,690Nov 17, 2026
Lazarus Howard
Officer: Chief Medical Officer
Sale11,023USD 27.80US$306KNov 17, 2026
Lazarus Howard
Officer: Chief Medical Officer
Sale2,066USD 28.27US$58,410Nov 17, 2026
Lazarus Howard
Officer: Chief Medical Officer
Sale211USD 29.27US$6,176Nov 17, 2026
FMR LLC
10% owner, Other: See Remark 1
Sale5,565USD 29.56US$165KNov 10, 2026
FMR LLC
10% owner, Other: See Remark 1
Sale47,889USD 30.28US$1.45MNov 10, 2026
FMR LLC
10% owner, Other: See Remark 1
Sale173,661USD 29.06US$5.05MNov 9, 2026
FMR LLC
10% owner, Other: See Remark 1
Sale1,339USD 29.75US$39,835Nov 9, 2026
Novo Holdings A/S
10% owner
Buy555,555USD 18.00US$10MMay 1, 2026
George Simeon
10% owner
Buy277,778USD 18.00US$5MMay 1, 2026
George Simeon
10% owner
Buy277,777USD 18.00US$5MMay 1, 2026
Carroll Jill
Director
Buy277,778USD 18.00US$5MMay 1, 2026

Big stakes

StakeStakeSharesDateFiling
FMR LLC13.20%5.84MJun 30, 2026Schedule 13G
Novo Holdings A/S8.80%3.88MJun 30, 2026Schedule 13G
SR One Capital Management, LLC7.50%3.31MMay 1, 2026Schedule 13D
Perceptive Advisors LLC6.00%2.68MApr 30, 2026Schedule 13G
Montanova Capital, LLC5.60%2.5MMay 1, 2026Schedule 13D
Norwest Venture Partners XV, LP5.10%2.27MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Heather Turner
Other companies: LB Pharmaceuticals Inc (Chief Executive Officer, Director · Since at least Sep 10, 2025); Terns Pharmaceuticals, Inc. (Director · Since at least Nov 18, 2024); Lyell Immunopharma, Inc. (Chief General Counsel · Jun 16, 2021 – Mar 16, 2022 · Past); Sangamo Therapeutics, Inc. (EVP, General Counsel & Sec. · Feb 12, 2018 – Feb 25, 2019 · Past); Atara Biotherapeutics, Inc. (Former EVP, GC & Sec. · Feb 6, 2018 – Feb 9, 2018 · Past)
Director · Since at least Apr 29, 2026
Erin Lavelle
Other companies: Jade Biosciences, Inc. (Director · Since at least Apr 28, 2025); Neurogene Inc. (Director · May 12, 2022 – Jun 8, 2023 · Past); Climb Bio, Inc. (COO & CFO · Aug 9, 2021 – Oct 31, 2022 · Past); Alder BioPharmaceuticals Inc (Chief Operating Officer · Apr 16, 2018 – Oct 22, 2019 · Past)
Director · Since at least Apr 29, 2026
Jill Carroll
Other companies: Arcellx Inc (Director · Since at least Feb 3, 2022); Pandion Therapeutics Inc (Director · Apr 1, 2021 – Apr 1, 2021 · Past)
Director · Since at least Apr 29, 2026
Jon Congleton
Other companies: Immunic, Inc. (Director · Since at least Mar 27, 2026); Mineralys Therapeutics, Inc. (Chief Executive Officer, Director · Since at least Feb 9, 2023)
Director · Since at least Apr 29, 2026
Jon Congleton
Other companies: Mineralys Therapeutics, Inc. (Chief Executive Officer · Since at least Oct 2, 2026); Immunic, Inc. (Independent Director · Since at least May 13, 2026)
Since at least Apr 6, 2026
Robert J. Meyer
Other companies: Chimerix Inc (Director · Jun 20, 2024 – Apr 21, 2025 · Past)
Director · Since at least Sep 15, 2026
Adam GoldenGeneral Counsel and Head of Business Development · Since at least Jun 3, 2026
Craig ConoscentiSenior Vice President, Clinical Development · Since at least May 21, 2026
David FriedmanMANAGING DIRECTOR AND SENIOR ANALYST, Suvretta Capital Management · Since at least Nov 5, 2026
Doug CarlsonChief Financial Officer and Chief Business Officer · Since at least Nov 4, 2026
All 20 people
PersonSeat
Frank SalisburySenior Vice President, Commercial · Since at least Jun 3, 2026
Howard M. LazarusChief Medical Officer · Since at least May 21, 2026
Jill DenningSenior Vice President, Clinical Development Operations · Since at least Nov 4, 2026
Jim BishopSenior Vice President, Business Operations · Since at least Nov 4, 2026
Kate HavilandSince at least Nov 4, 2026
Kelly DonoghueSr. Manager, IR and Corporate Communications · Since at least Nov 3, 2026
Kimberley CummingsSENIOR VICE PRESIDENT, REGULATORY AFFAIRS · Since at least Nov 5, 2026
Lyn BaranowskiChief Executive Officer · Since at least Sep 16, 2026
Melissa RhodesChief Operating Officer · Since at least Apr 29, 2026
Stephen PhamSenior Vice President, Product Development · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Avalyn Pharma Inc.